Schedule 13G: Lind Global Reports 1,005,961 Shares (9.9%) of BNGO

Rhea-AI Filing Summary

Bionano Genomics (BNGO) received a Schedule 13G disclosing that Lind Global Fund III LP and related reporting persons beneficially own 1,005,961 shares of common stock, representing 9.9% of the class. The disclosed position comprises 525,000 shares, 525,000 Series E warrants and 525,000 Series F warrants, and the filing explicitly states the warrants may not be exercised to cause ownership to exceed 9.9%. The filing identifies Lind Global Partners III LLC as the general partner and Jeff Easton as managing member, with sole voting and dispositive power over the reported holdings. The reporting persons certify the holdings were not acquired to change or influence control.

Positive

• Clear disclosure of aggregate beneficial ownership (1,005,961 shares) and percentage (9.9%).
• Explicit description of holdings composition: 525,000 shares, 525,000 Series E warrants, and 525,000 Series F warrants.
• Warrant exercise limitation stated: warrants may not be exercised if exercise would cause beneficial ownership to exceed 9.9%, limiting immediate ownership escalation.
• Identification of control relationships: Lind Global Partners III LLC as GP and Jeff Easton as managing member with sole voting and dispositive power.

Negative

• None.

Insights

Financial Analyst

TL;DR: A disclosed 9.9% passive stake with warrants capped to avoid exceeding the 9.9% threshold.

The filing reports an aggregate beneficial ownership of 1,005,961 shares (9.9%), composed of common shares and warrants. The explicit exercise limitation on warrants is material because it constrains immediate dilution or conversion risk to the company’s share count and prevents automatic crossing of the 10% reporting/beneficial ownership threshold. The structure indicates an economically significant position while maintaining a passive filing status under Schedule 13G.

Corporate Governance Expert

TL;DR: Ownership disclosed clearly; reporting persons affirm no intent to influence control.

The Schedule 13G names the entities and individual with sole voting and dispositive power and includes a certification that the securities are not held to influence control. For governance purposes, this provides transparency about a near-10% holder and clarifies control relationships among the fund, its GP, and the managing member. The attached Joint Filing Agreement is noted as Exhibit 99.1, documenting coordination among the reporting persons.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Bionano Genomics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

09075F404

(CUSIP Number)

09/17/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 09075F404

1

Names of Reporting Persons

Lind Global Fund III LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,005,961.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,005,961.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,005,961.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The reporting person's ownership consists of (i) 525,000 shares of common stock, (ii) 525,000 warrants to purchase shares of common stock (the "Series E Warrants") and (iii) 525,000 shares of common stock (the "Series F Warrants"). Such warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.

SCHEDULE 13G

CUSIP No. 09075F404

1

Names of Reporting Persons

Lind Global Partners III LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,005,961.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,005,961.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,005,961.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The reporting person's ownership consists of (i) 525,000 shares of common stock, (ii) 525,000 warrants to purchase shares of common stock (the "Series E Warrants") and (iii) 525,000 shares of common stock (the "Series F Warrants"). Such warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.

SCHEDULE 13G

CUSIP No. 09075F404

1

Names of Reporting Persons

Jeff Easton

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,005,961.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,005,961.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,005,961.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The reporting person's ownership consists of (i) 525,000 shares of common stock, (ii) 525,000 warrants to purchase shares of common stock (the "Series E Warrants") and (iii) 525,000 shares of common stock (the "Series F Warrants"). Such warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Bionano Genomics, Inc.
(b)	Address of issuer's principal executive offices: 9540 Towne Centre Drive, Suite 100, San Diego, California, 92121
Item 2.
(a)	Name of person filing: This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"): o Lind Global Fund III LP, a Delaware limited partnership; o Lind Global Partners III LLC, a Delaware limited liability company; and o Jeff Easton, an individual and a citizen of the United States of America. Lind Global Partners III LLC, the general partner of Lind Global Fund III LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP. Jeff Easton, the managing member of Lind Global Partners III LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP.
(b)	Address or principal business office or, if none, residence: The address of the principal business office for each of the Reporting Persons is: 444 Madison Ave, Floor 41 New York, NY 10022
(c)	Citizenship: See Row 4 of cover page for each Reporting Person.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 09075F404
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of cover page for each Reporting Person.
(b)	Percent of class: See Row 11 of cover page for each Reporting Person.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lind Global Fund III LP

Signature:	By: Lind Global Partners III LLC, its General Partner, By: /s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	09/24/2025

Lind Global Partners III LLC

Signature:	/s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	09/24/2025

Jeff Easton

Signature:	/s/ Jeff Easton
Name/Title:	Jeff Easton
Date:	09/24/2025

Exhibit Information

99.1 Joint Filing Agreement by and among the Reporting Persons.

FAQ

How many BNGO shares does Lind Global Fund III LP report owning?

The reporting persons disclose beneficial ownership of 1,005,961 shares, representing 9.9% of the class.

What securities comprise the reported 9.9% position in BNGO?

The position consists of 525,000 common shares, 525,000 Series E warrants, and 525,000 Series F warrants.

Can the warrants be exercised to increase ownership above 9.9%?

No; the filing states the warrants may not be exercised if such exercise would cause the reporting person's beneficial ownership to exceed 9.9%.

Who has voting and dispositive power over the reported BNGO securities?

Lind Global Partners III LLC (the general partner) and Jeff Easton (managing member) are reported to have sole voting and sole dispositive power over the holdings.

Did the reporting persons indicate intent to influence control of Bionano Genomics?

The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.